Why choose Tresiba® FlexTouch® U-100?

When prescribing basal insulin, did you know you have another U-100 option? Watch this video to find out why Tresiba® FlexTouch® U-100 may be a more appropriate option for your patients 1 year of age and older with diabetes.  

Tresiba® FlexTouch® U-100

Full Prescribing Information Important Safety Information

USA17TSM04073

Show your patients how to use Tresiba® FlexTouch®

Watch IFU video

primary_msg

Start your patients new to insulin on their journey with Tresiba®

More administration options than any other basal insulin1-5

Tresiba® FlexTouch® U‑1001

The U-100 you're familiar with

U-100 Green Injector

Pen contains 300 total units 

Delivers a maximum dose of 80 units in a single injection

1-unit dose adjustments

Tresiba® FlexTouch®
U‑2001

Same dose in half the volume of U-100

U200 Dark Green Injector

Pen contains 600 total units

Patients who need higher doses can take up to 160 units in a single injection

2-unit dose adjustments

Tresiba® U-100 multiple-dose 10-mL vial1

For patients who prefer vials

U100 Vial

Vial contains 1000 total units

Use vial only with a U-100 insulin syringe

Unit dosing remains the same, no matter which administration option you prescribe

secondary_msg

Tresiba® has one of the longest in-use times of any once-daily, long-acting basal insulin1-4

FlexTouch® Timing Chart

aOpened (in-use) Tresiba® should be refrigerated (36°F to 46°F [2°C to 8°C]) or kept at room temperature (below 86°F [30°C]), away from direct heat and light.1
bOpened (in-use) Lantus® SoloSTAR® devices must be discarded 4 weeks after being opened. Once in use, the device must be kept at room temperature and should not be refrigerated.2
cThe in-use insulin glargine U-100 vial must be discarded after 4 weeks and the in-use insulin detemir pen and vial must be discarded after 6 weeks.2,3

tertiary_msg

Eligible patients may pay as little as $5 for a 30-day supply of Tresiba®d

Help patients save

dFor up to 24 months. Maximum savings of $150 per 30-day supply. Eligibility and other restrictions apply.

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
    • Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
    • Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
    • Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

Please click here for Prescribing Information

 

 

References:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2019.
  2. Lantus [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; November 2018.
  3. Levemir [package insert]. Plainsboro, NJ: Novo Nordisk Inc; March 2020.
  4. Basaglar [package insert]. Indianapolis, IN: Lilly USA LLC; September 2018.
  5. Toujeo [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; March 2019.